Babesia microti Antigen Compositions for Prophylaxis and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human babesiosis caused by Babesia microti is difficult to treat, especially in immunocompromised individuals, and there is a lack of effective prophylactic measures and vaccines, leading to severe complications and high mortality rates.
Innovation Solution
Development of compositions containing Babesia microti antigens with specific amino acid sequences, either alone or in combination with antibodies, to provide immunization and treatment options, including nucleic acid molecules encoding these antigens, and adjuvants for enhanced immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimicrobial therapy (atovaquone and azithromycin) is used to treat babesiosis, then treatment can be provided, but treatment is difficult particularly in immunocompromised individuals and severe complications occur
Solution Approach 1:
The patent uses antibodies as intermediary substances that specifically bind to Babesia microti parasites. These antibodies act as mediators between the host immune system and the parasite, enabling targeted neutralization of the pathogen without requiring the host to mount a full immune response, thus treating immunocompromised individuals who cannot effectively mount their own immune responses
Solution Approach 2:
The patent employs recombinant antibodies that replicate the protective immune response naturally generated against Babesia microti. These engineered antibody copies provide the same protective function as natural antibodies would, allowing passive transfer of immunity to patients who cannot produce sufficient protective antibodies themselves
2Reliability
If no vaccine or prophylactic antibiotic regimen is available, then current treatment options are limited, but this leaves no preventive measures for high-risk individuals
Solution Approach 1:
The patent enables preliminary protective action through passive antibody transfer and active vaccination approaches. By administering antibodies or antigen compositions before exposure or at the onset of infection, the system provides preemptive protection rather than waiting for disease development and treatment
Solution Approach 2:
The patent changes the parameter of immune protection from active (requiring host immune system function) to passive (providing ready-made antibodies), making prophylaxis available to immunocompromised individuals who cannot mount effective active immune responses
Data Source
AI summary
Described herein are compositions that comprise one or more Babesia microti antigens, one or more Babesia microti nucleic acid molecules, or one or more anti-Babesia microti antibodies and uses thereof in methods for the prophylaxis of babesiosis, the treatment of babesiosis and the monitoring of individuals undergoing prophylactic or therapeutic administration of the compositions of the invention.